Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
ALS
|
NINDS
|
5U01NS050094-03
|
|
Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis
|
ROTHSTEIN, JEFFREY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$322,944
|
ALS
|
NIGMS
|
5R01GM054111-11
|
|
Copper Protein In Metal and Oxidant Stress Responses
|
O'HALLORAN, THOMAS
|
NORTHWESTERN UNIVERSITY
|
IL
|
$311,439
|
ALS
|
NINDS
|
5R01NS046615-04
|
|
Heat Shock Proteins and Motoneuron Survival
|
MILLIGAN, CAROL
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$314,648
|
ALS
|
NINDS
|
5R01NS036548-07
|
|
AMPA/Kainate Receptors, Free Radicals, And Motor Neuron Injury
|
WEISS, JOHN
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$333,174
|
ALS
|
NINDS
|
5R01NS050557-04
|
|
High-Throughput Genomic Approaches to Identify ALS Genes
|
BROWN, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$495,019
|
ALS
|
NINDS
|
5R01NS033958-13
|
|
Neuronal vs. glial glutamate transport regulation in ALS
|
ROTHSTEIN, JEFFREY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$424,354
|
ALS
|
NINDS
|
5R01NS038679-08
|
|
Non-viral Delivery of Neurotrophic Factors to the CNS
|
FRANCIS, JONATHAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$544,805
|
ALS
|
NIGMS
|
5F31GM077078-03
|
|
Role of Yeast Sen1p in RNA Maturation Pathways (Predoctoral Fellowhips for Studen
|
FINKEL, JONATHAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$29,907
|
ALS
|
NINDS
|
5R21NS054934-02
|
|
Identification of Protein Biomarkers for ALS
|
LIU, JIAN
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
CA
|
$240,188
|
ALS
|
NINDS
|
5U01NS049640-04
|
|
Clinical Trial of Ceftriaxone in ALS
|
CUDKOWICZ, MERIT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$6,125,934
|
ALS
|
NINDS
|
5R01NS051288-03
|
|
Imaging Mitochondrial Function in Excitotoxicity
|
SHUTTLEWORTH, CLAUDE
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$260,323
|
ALS
|
NINDS
|
5R01NS040494-08
|
|
Bicarbonate Enhances Peroxidation of SOD/ALS Mutants
|
KALYANARAMAN, BALARAMAN
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$285,958
|
ALS
|
NINDS
|
5R01NS052325-03
|
|
Trophic Factor Signaling and Motor Neuron Death
|
KALB, ROBERT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$287,877
|
ALS
|
NINDS
|
5R01NS051723-03
|
|
Time-lines of neural degeneration in ALS-PDC mouse model
|
SHAW, CHRISTOPHER
|
UNIVERSITY OF BRITISH COLUMBIA
|
CANADA
|
$262,170
|
ALS
|
NINDS
|
5R01NS055746-02
|
|
Mechanisms of motor neuron toxicity in Kennedy Disease
|
LIEBERMAN, ANDREW
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$319,214
|
ALS
|
NINDS
|
1R01NS055315-01A2
|
|
Mechanisms of SOD1 toxicity in ALS
|
ELLIOTT, JEFFREY
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$309,094
|
ALS
|
NINDS
|
1R01NS058888-01A1
|
|
Ca2+ mishandling and ischemia-vulnerability in fALS model motor terminals
|
DAVID, GAVRIEL
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$301,219
|
ALS
|
NIGMS
|
5R01GM080742-02
|
|
Protein misfolding and aggregation
|
DOKHOLYAN, NIKOLAY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$261,936
|
ALS
|
NINDS
|
5R21NS058538-02
|
|
Aberrant VEGF RNA Stability in Amyotrophic Lateral Sclerosis
|
KING, PETER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$158,594
|
ALS
|
NIGMS
|
2R01GM064631-06
|
|
Structure/Function of Mn and Fe Superoxide Dismutases and Related Enzymes
|
BRUNOLD, THOMAS
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$219,826
|
ALS
|
NINDS
|
5R21NS053770-02
|
|
Silencing mutant SOD1 in vivo for treatment of ALS
|
XU, ZUOSHANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$178,403
|
ALS
|
NIDCD
|
5R01DC003723-09
|
|
Articulatory Kinematics in Neurogenic Speech Disorders
|
WEISMER, GARY
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$486,725
|
ALS
|
NINDS
|
5K23NS055200-02
|
|
Pilot Placebo-Controlled Trial of Early Noninvasive Ventilation for ALS
|
GRUIS, KIRSTEN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$173,340
|
ALS
|
NINDS
|
5R01NS048145-05
|
|
Understanding mechanism and therapy of ALS using RNAi
|
XU, ZUOSHANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$348,635
|
ALS
|
NINDS
|
5R01NS051462-04
|
|
Increased persistent sodium current in SOD1 motoneurons
|
HECKMAN, CHARLES
|
NORTHWESTERN UNIVERSITY
|
IL
|
$314,445
|
ALS
|
NINDS
|
5R01NS040014-07
|
|
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis
|
WONG, PHILIP
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$358,750
|
ALS
|
NINDS
|
5R01NS045893-05
|
|
Prospective Epidemiological Study of ALS
|
ASCHERIO, ALBERTO
|
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
|
MA
|
$290,173
|
ALS
|
NINDS
|
1F32NS059155-01A1
|
|
Transplantation of glial precursors: Astrocyte replacement in ALS
|
LEPORE, ANGELO
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$55,778
|
ALS
|
NINDS
|
5R37NS027036-21
|
|
Neurofilaments, SOD1 and Motor Neuron Diseases
|
CLEVELAND, DON
|
LUDWIG INSTITUTE FOR CANCER RESEARCH
|
CA
|
$576,188
|
ALS
|
NINDS
|
1F31NS060532-01A1
|
|
Synaptic & intrinsic motoneuron excitability in ALS excitotoxicity
|
SCHUSTER, JENNA
|
NORTHWESTERN UNIVERSITY
|
IL
|
$40,972
|
ALS
|
NIGMS
|
5R01GM054836-12
|
|
Folding Mechanisms of Dimeric Beta-Barrel Proteins
|
MATTHEWS, C
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$277,343
|
ALS
|
NINDS
|
5R01NS050641-05
|
|
Genetics of ALS
|
SIDDIQUE, TEEPU
|
NORTHWESTERN UNIVERSITY
|
IL
|
$710,637
|
ALS
|
NINDS
|
5R01NS051419-03
|
|
The Pathogenic Mechanisms of Mutant SOD1 in Mitochondria
|
MANFREDI, GIOVANNI
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$293,630
|
ALS
|
NINDS
|
5R01NS041646-09
|
|
Identification of genes that delay ALS onset
|
KUNST, CATHERINE
|
UNIVERSITY OF DENVER
|
CO
|
$337,890
|
ALS
|
NINDS
|
5R01NS041648-08
|
|
MODELS OF SBMA MOTOR NEURON DEGENERATION
|
LA SPADA, ALBERT
|
UNIVERSITY OF WASHINGTON
|
WA
|
$332,409
|
ALS
|
NINDS
|
5R01NS051764-03
|
|
The Role of Iduna in Neuroprotection
|
DAWSON, VALINA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$398,110
|
ALS
|
NCCAM
|
5R21AT003632-02
|
|
A modified dietary regiment as a potential novel therapeutic intervention in ALS.
|
PASINETTI, GIULIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$207,638
|
ALS
|
NINDS
|
5R01NS050674-04
|
|
Spatial Considerations in Neuronal Survival Signals
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$374,947
|
ALS
|
NINDS
|
5R03NS054969-02
|
|
Neurotoxicity of sterol glucosides: role in ALS-PDC
|
SHAW, CHRISTOPHER
|
UNIVERSITY OF BRITISH COLUMBIA
|
CANADA
|
$33,233
|
ALS
|
NINDS
|
5R01NS039112-08
|
|
X-ray Studies of SOD in Amyotrophic Lateral Sclerosis
|
HART, PETER
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$318,974
|
ALS
|
NINDS
|
5R01NS040819-06
|
|
Mechanisms of Protection and Pathogenesis in Amyotrophic Lateral Sclerosis Mice
|
CROW, JOHN
|
UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
|
AR
|
$372,125
|
ALS
|
NICHD
|
5R44HD053176-03
|
|
Reliable and Safe Laser Pointing for People with Locked-in Syndrome
|
JAKOBS, THOMAS
|
INVOTEK, INC.
|
AR
|
$169,513
|
ALS
|
NINDS
|
5R21NS054754-02
|
|
Identifying Pathogenic Protein Aggregates in ALS through Autocatalytic Misfolding
|
BOSQUE, PATRICK
|
DENVER HEALTH AND HOSPITAL AUTHORITY
|
CO
|
$151,080
|
ALS
|
NINDS
|
5R01NS056422-02
|
|
Role of Fas death receptor signaling in motor neuron degeneration
|
HENDERSON, CHRISTOPHER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$352,188
|
ALS
|
NINDS
|
5K08NS056212-03
|
|
Nogo's role in intracellular trafficking
|
HAREL, NOAM
|
YALE UNIVERSITY
|
CT
|
$158,765
|
ALS
|
NINDS
|
1K99NS062089-01
|
|
Mechanism of SOD1-linked ALS studied in C elegans and mouse models
|
WANG, JIOU
|
YALE UNIVERSITY
|
CT
|
$90,000
|
ALS
|
NINDS
|
1R21NS062180-01
|
|
Early motor neuron alteration in a non-cell autonomous ALS model
|
PRZEDBORSKI, SERGE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$203,740
|
ALS
|
NIEHS
|
5R01ES014469-03
|
|
Effect of Variation in Genes of Xenobiotic Responsive Proteins in ALS
|
SIDDIQUE, TEEPU
|
NORTHWESTERN UNIVERSITY
|
IL
|
$574,595
|
ALS
|
NINDS
|
1R21NS062230-01
|
|
Modeling TDP-43 Dysfunction in vivo
|
XU, ZUOSHANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$177,734
|
ALS
|
NIDCD
|
5R01DC006859-05
|
|
Perception of Dysarthric Speech
|
LISS, JULIE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$285,331
|
ALS
|
NIA
|
5R21AG029808-02
|
|
Proteomic Discovery in Parkinson-Dementia Complex of Guam
|
MONTINE, THOMAS
|
UNIVERSITY OF WASHINGTON
|
WA
|
$188,042
|
ALS
|
NIDCD
|
5R01DC004689-07
|
|
Therapeutic Approaches to Dysarthria: Acoustic and Perceptual Correlates
|
TJADEN, KRIS
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
NY
|
$259,304
|
ALS
|
NINDS
|
1R01NS054739-01A2
|
|
Transciption Factor Codes, Guidance Receptors and Motor Axon Guidance
|
BASHAW, GREG
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$315,000
|
ALS
|
NINDS
|
1R01NS059708-01A1
|
|
Transgenic models of ALS caused by VAPB mutation
|
XU, ZUOSHANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$355,469
|
ALS
|
NICHD
|
1R21HD054913-01A2
|
|
Tilt/Recline Adjustment by Subjects with ALS using Brain Computer Interfaces
|
HUGGINS, JANE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$258,183
|
ALS
|
NIGMS
|
5R37GM050016-16
|
|
Genetic Determinants of Oxygen Toxicity
|
CULOTTA, VALERIA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$326,554
|
ALS
|
NINDS
|
1R03NS057693-01A2
|
|
Increasing DNA marker informativeness in hereditary canine motor neuron disease
|
PINTER, MARTIN
|
EMORY UNIVERSITY
|
GA
|
$76,500
|
ALS
|
NINDS
|
5F32NS055547-03
|
|
Genetic Analysis of Fas in Motor Neuron Cell Death
|
KANNING, KEVIN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$48,796
|
ALS
|
NINDS
|
5R01NS052179-04
|
|
Therapeutic Expression of Glial Glutamate Transporters
|
ROTHSTEIN, JEFFREY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$358,502
|
ALS
|
NIEHS
|
5R01ES013244-05
|
|
Genetic Epidemiology of ALS in Veterans
|
SCHMIDT, SILKE
|
DUKE UNIVERSITY
|
NC
|
$433,467
|
ALS
|
NIA
|
5R37AG013617-14
|
|
METABOTROPIC GLUTAMATE RECEPTORS IN NEURODEGENERATION
|
YOUNG, ANNE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$324,784
|
ALS
|
NINDS
|
5K01NS052183-04
|
|
Toxic Probes of Axonopathy
|
TSHALA-KATUMBAY, DANIEL
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$156,814
|
ALS
|
NINDS
|
5R01NS049126-05
|
|
Proteomic and Functional Studies of Mitochondria in ALS
|
ZHU, HAINING
|
UNIVERSITY OF KENTUCKY
|
KY
|
$253,622
|
ALS
|
NINDS
|
1R21NS061257-01A1
|
|
Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools
|
SIERKS, MICHAEL
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$176,394
|
ALS
|
NINDS
|
1R13NS062463-01
|
|
International Meeting on Plasticity and Disease of Motoneurons
|
BINDER, MARC
|
UNIVERSITY OF WASHINGTON
|
WA
|
$10,000
|
ALS
|
NINDS
|
1U13NS062682-01
|
|
Accelerating ALS Research: Translating Basic discoveries into Therapies for ALS
|
BRUIJN, LUCIE
|
AMYOTROPIC LATERAL SCLEROSIS ASSOCIATION
|
CA
|
$25,000
|
ALS
|
OD
|
1U13NS062682-01
|
|
Accelerating ALS Research: Translating Basic discoveries into Therapies for ALS
|
BRUIJN, LUCIE
|
AMYOTROPIC LATERAL SCLEROSIS ASSOCIATION
|
CA
|
$25,000
|
ALS
|
NINDS
|
1F31NS062583-01
|
|
Mechanisms of Virus Induced Motor Neuron Injury and Treatment of Viral Myelitis
|
SCHITTONE, STEPHANIE
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$32,772
|
ALS
|
NINDS
|
1F31NS062627-01
|
|
The Role of the Intrinsic Apoptotic Pathway in Familial ALS
|
REYES, NICHOLE
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$30,865
|
ALS
|
NINDS
|
5U01NS052225-02
|
|
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
|
BROWN, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$629,008
|
ALS
|
NINDS
|
5R01NS051488-04
|
|
SOD1/Bc1-2 Complex: A Role in Regulating Motor Neuron Cell Death
|
PASINELLI, PIERA
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$417,531
|
ALS
|
NINDS
|
5R21NS060182-02
|
|
Proteomic Markers for ALS
|
GLASS, JONATHAN
|
EMORY UNIVERSITY
|
GA
|
$167,344
|
ALS
|
NIMH
|
5R21EY018491-02
|
|
Gene Delivery to the CNS through the Deep Cerebellar Nucleus
|
KASPAR, BRIAN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$176,400
|
ALS
|
NINDS
|
5R01NS052514-02
|
|
Cortex Changes in Real/Imagined Movement in ALS
|
WELSH, ROBERT
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$375,643
|
ALS
|
NINDS
|
5U44NS059084-02
|
|
Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
KARLSSON, JENNY
|
MAAS BIOLAB, INC.
|
NM
|
$894,021
|
ALS
|
NINDS
|
1K08NS062890-01
|
|
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
|
LLOYD, THOMAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$175,635
|
ALS
|
NIA
|
1R21AG032567-01
|
|
Role of p62 in Protein Aggregation and Neurodegeneration in ALS
|
ZHU, HAINING
|
UNIVERSITY OF KENTUCKY
|
KY
|
$231,250
|
ALS
|
NINDS
|
1R01NS060698-01A1
|
|
Mechanistic analysis of axonal transport defects in motor neuron degenerative dis
|
HOLZBAUR, ERIKA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$344,531
|
ALS
|
NIA
|
1R01AG029368-01A1
|
|
A Novel Neuroprotective Protein, Thorase
|
DAWSON, VALINA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$334,970
|
ALS
|
NINDS
|
1R01NS058628-01A2
|
|
Superoxide Dismutase, Peroxynitrite and ALS
|
BECKMAN, JOSEPH
|
OREGON STATE UNIVERSITY
|
OR
|
$319,813
|
ALS
|
NINDS
|
1R01NS058980-01A2
|
|
Genetics of Gene Expression and Gene Mapping for Amytrophic Lateral Sclerosis
|
OPHOFF, ROEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$330,250
|
ALS
|
NINDS
|
1R21NS060754-01A2
|
|
Abnormal Energy Homeostasis in ALS
|
KALB, ROBERT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$179,922
|
ALS
|
NINDS
|
1R21NS061049-01A1
|
|
Stem cell therapy targeting skeletal muscles for ALS
|
SUZUKI, MASATOSHI
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$194,906
|
ALS
|
NINDS
|
1R21NS058430-01A1
|
|
Selective CB2 Cannabinoid Agonists as Candidate Therapeutics for ALS
|
PRATHER, PAUL
|
UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
|
AR
|
$188,053
|
ALS
|
NINDS
|
1R43NS063483-01
|
|
Novel Therapeutic for Amyotrophic Lateral Sclerosis (ALS)
|
SMITH, DAVID
|
ANGION BIOMEDICA CORPORATION
|
NY
|
$184,012
|
ALS
|
NINDS
|
1F32NS061464-01A1
|
|
Molecular basis of age-related synaptic alterations
|
VALDEZ, GREGORIO
|
HARVARD UNIVERSITY
|
MA
|
$51,278
|
ALS
|
NINDS
|
5F30NS060387-02
|
|
Combined Stem Cell and Anti-Oxidative Therapy for ALS
|
THONHOFF, JASON
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$27,187
|
ALS
|
RMAP
|
1DP1OD003930-01
|
|
Use of induced pluripotent stem cells to study mechanims of familial and sporadic
|
MANIATIS, THOMAS
|
HARVARD UNIVERSITY
|
MA
|
$835,500
|
ALS
|
NINDS
|
1R01NS064253-01
|
|
Pathogenesis of Neurodegenerative Diseases Caused by Mutations in Senataxin
|
NAGY, PETER
|
UNIVERSITY OF IOWA
|
IA
|
$328,125
|
ALS
|
NINDS
|
1R01NS064133-01
|
|
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing
|
KING, PETER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$307,344
|
ALS
|
NINDS
|
1K08NS057664-01A2
|
|
Dysregulation of VEGF RNA Stability in Amyotrophic Lateral Sclerosis
|
LU, LIANG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$145,800
|
ALS
|
NINDS
|
1R21NS062189-01A1
|
|
Target Validation for Neurogenerative Disease Using Conditional RNAi in vivo
|
MAXWELL, MICHELE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$205,980
|
ALS
|
NINDS
|
1R01NS060874-01A2
|
|
Brain Metabolic Imaging in Amyotrophic Lateral Sclerosis
|
GOVINDARAJU, VARANAVASI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$296,118
|
ALS
|
NINDS
|
1R01NS062766-01A1
|
|
Regulation of mitochondrial oxidative stress by Bcl-2 family proteins
|
LINSEMAN, DANIEL
|
UNIVERSITY OF DENVER
|
CO
|
$320,141
|
ALS
|
NINDS
|
1R21NS061084-01A2
|
|
CSF Indicators for Diagnosis and Disease Progression of ALS
|
MILLIGAN, CAROL
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$194,250
|
ALS
|
NINDS
|
5P01NS057778-02
|
0001
|
Respiratory Plasticity in the SOD1g93a Rat
|
MITCHELL, GORDON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$343,651
|
ALS
|
NINDS
|
5P01NS057778-02
|
0002
|
Astrocytes Producting Growth Factors for ALS
|
SVENDSEN, CLIVE
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$327,191
|
ALS
|
NINDS
|
5P01NS057778-02
|
0003
|
Replacement of Motor Neurons and Astrocytes in ALS Using Human Embryonic Stem Cel
|
ZHANG, SU-CHUN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$327,611
|
ALS
|
NIA
|
5P50AG016574-10
|
0005
|
Genetics of Frontotemporal Dementia (FTD) and Motor Neuron Disease
|
HUTTON, MICHAEL
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$190,140
|
ALS
|
NINDS
|
5P01NS049134-04
|
0002
|
Structural and Biophysical Properties of Oligermeric SOD1
|
HART, P
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$338,003
|
ALS
|
NINDS
|
5P01NS049134-04
|
0003
|
Testing Hypotheses by Site Directed Mutagenesis of SOD1
|
BORCHELT, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$358,786
|
ALS
|
NINDS
|
5P01NS049134-04
|
9001
|
Analytical
|
WHITELEGGE, JULIAN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$189,545
|
ALS
|
NINDS
|
3R01NS052325-03S1
|
|
Trophic Factor Signaling and Motor Neuron Death
|
KALB, ROBERT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$96,625
|
ALS
|
NIA
|
5P30AG013854-13
|
9001
|
CORE--CLINICAL
|
WEINTRAUB, SANDRA
|
NORTHWESTERN UNIVERSITY
|
IL
|
$593,611
|
ALS
|
NIA
|
5P30AG013854-13
|
9003
|
CORE--NEUROPATHOLOGY
|
BIGIO, EILEEN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$255,241
|
ALS
|
NINDS
|
3R01NS048125-04S3
|
|
Clinical Trial of High Dose Coenzyme Q10 in Amyotrophic lateral Sclerosis
|
KAUFMANN, PETRA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$40,000
|
ALS
|
NINDS
|
3R01NS049126-05S1
|
|
Proteomic and Functional Studies of Mitochondria in ALS
|
ZHU, HAINING
|
UNIVERSITY OF KENTUCKY
|
KY
|
$73,250
|
ALS
|
NIA
|
5P01AG019724-07
|
0004
|
CLINICAL CRITERIA
|
MILLER, BRUCE
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$275,881
|
ALS
|
NIA
|
5P01AG019724-07
|
9001
|
CLINICAL AND ADMINISTRATIVE
|
MILLER, BRUCE
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$568,456
|
ALS
|
NINDS
|
3U01NS049640-04S1
|
|
Clinical Trial of Ceftriaxone in ALS
|
CUDKOWICZ, MERIT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$1,000,000
|
ALS
|
NINDS
|
5U54NS039407-09
|
0006
|
Manganese Superoxide Dismutase in Mechanisms of Aging and Neurodgeneration
|
DUTTAROY, ATANU
|
HOWARD UNIVERSITY
|
DC
|
$237,000
|
ALS
|
NIGMS
|
3R01GM080742-02S1
|
|
Protein misfolding and aggregation
|
DOKHOLYAN, NIKOLAY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$27,706
|
ALS
|
NIA
|
Y2AG9075-24-0-1
|
|
Assessment of Primate Aging: Effects of Caloric Modification
|
NO PI IDENTIFIED
|
|
|
$1,300,000
|
ALS
|
NCRR
|
5M01RR000071-45
|
8284
|
USE OF PYRIMETHAMINE IN FAMILIAL ALS
|
LANGE, DALE
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$24,541
|
ALS
|
NCRR
|
5M01RR007122-17
|
8352
|
CLINICAL TRIAL: CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS
|
CARESS, JAMES
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$45,936
|
ALS
|
NCRR
|
5M01RR023940-02
|
8458
|
CLINICAL TRIAL: COQ10 IN ALS
|
BAROHN, RICHARD
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$11,733
|
ALS
|
NCRR
|
5M01RR000064-44
|
8615
|
CLINICAL TRIAL: EARLY TREATMENT OF ALS WITH NUTRITION AND NIPPV
|
BROMBERG, MARK
|
UNIVERSITY OF UTAH
|
UT
|
$3,438
|
ALS
|
NCRR
|
5M01RR000034-48
|
8724
|
CLINICAL TRIAL: CLINICAL TRIAL OF IGF-1 IN PATIENTS WITH AMYOTROPHIC LATERAL SCL
|
NASH, STEPHEN
|
OHIO STATE UNIVERSITY
|
OH
|
$2,079
|
ALS
|
NCRR
|
5M01RR000034-48
|
8752
|
STUDY OF SR 57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
|
KISSEL, JOHN
|
OHIO STATE UNIVERSITY
|
OH
|
$2,079
|
ALS
|
NCRR
|
5M01RR001346-27
|
8820
|
CLINICAL TRIAL: CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS
|
JACKSON, CARLAYNE
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$868
|
ALS
|
NCRR
|
5M01RR010732-14
|
8884
|
EARLY TREATMENT OF ALS W NUTRITION & NON-INVASIVE POSITIVE PRESSURE VENTILATION
|
SIMMONS, ZACHARY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$27,588
|
ALS
|
NCRR
|
5M01RR010732-14
|
5018
|
AN EVALUATION OF THE EFFECTS OF STRENGTH TRAINING ON ALS
|
SCOTT, KEVIN
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$13,793
|
ALS
|
NCRR
|
5M01RR010732-14
|
5034
|
IMPAIRED REASONING & SOCIAL JUDGE IN FRONTOTEMPORAL LOBAR DEGEN IN ALS
|
FLAHERTY-CRAIG, CLAIRE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$2,029
|
ALS
|
NCRR
|
5M01RR010732-14
|
5098
|
ALS NUTRITION
|
SIMMONS, ZACHARY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$6,086
|
ALS
|
NCRR
|
5M01RR001032-33
|
5153
|
DIAPHRAGM TRAINING IN AMYOTROPHIC LATERAL SCLEROSIS
|
NARDIN, RACHEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$141
|
ALS
|
NCRR
|
5M01RR000109-44
|
5427
|
CLINICAL TRIAL: CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS
|
TANDAN, RUP
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$38,217
|
ALS
|
NCRR
|
5M01RR000109-44
|
5428
|
CLINICAL TRIAL: EARLY TREATMENT OF ALS WITH NUTRITION AND NIPPV
|
TANDAN, RUP
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$50,956
|
ALS
|
NCRR
|
5M01RR000109-44
|
5436
|
MEASURING QUALITY OF LIFE IN INDIVIDUALS WITH AMYOTROPHIC LATERAL SCLEROSIS
|
TANDAN, RUP
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$4,496
|
ALS
|
NCRR
|
5M01RR000109-44
|
5445
|
RADIOLOGICAL CORRELATES OF COGNITIVE DYSFUNCTION IN ALS
|
TANDAN, RUP
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$11,989
|
ALS
|
NCRR
|
2P41RR001646-26
|
7416
|
CRYSTALLOGRAPHIC STUDIES OF SIGNALING PROTEINSC
|
CHEN, XIAOMIN
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$20,007
|
ALS
|
NCRR
|
5P41RR001209-29
|
7923
|
X-RAY ABSORPTION STUDIES OF MUTANTS OF COPPER/ZINC SUPEROXIDE DISMUTASE
|
DE BEER GEORGE, SERENA
|
STANFORD UNIVERSITY
|
CA
|
$962
|
ALS
|
NCRR
|
5P41RR001209-29
|
8092
|
AN ULTRAHIGH RESOLUTION CRYSTAL STRUCTURE OF CTX-M BETA-LACTAMASE FOR ENZYME STU
|
CHEN, YU
|
STANFORD UNIVERSITY
|
CA
|
$184
|
ALS
|
NCRR
|
5P41RR001209-29
|
8125
|
STRUCTURAL STUDIES OF FF DOMAINS
|
CHEN, XIAOMIN
|
STANFORD UNIVERSITY
|
CA
|
$184
|
ALS
|
NCRR
|
5P41RR008630-13
|
8857
|
SPINAL CORD METAL ACCUMULATION IN YOUNG ADULT AND AGED RAT
|
GERIN, CHRISTINE
|
ILLINOIS INSTITUTE OF TECHNOLOGY
|
IL
|
$18,984
|
ALS
|
NCRR
|
5P41RR011823-13
|
5905
|
ANALYZING MICROGLIA-DERIVED TOXICITY TO MOTOR NEURONS IN ALS
|
CLEVELAND, DON
|
UNIVERSITY OF WASHINGTON
|
WA
|
$8,075
|
ALS
|
NCRR
|
5M01RR000827-33
|
7111
|
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC
|
MOZAFFAR, TAHSEEN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$1,374
|
ALS
|
NCRR
|
5M01RR000827-33
|
7139
|
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY
|
MOZAFFAR, TAHSEEN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$1,831
|
ALS
|
NCRR
|
5M01RR000827-33
|
7141
|
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS
|
MOZAFFAR, TAHSEEN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$5,495
|
ALS
|
NCRR
|
2M01RR001066-31
|
8215
|
CLINICAL TRIAL: CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS
|
KRIVICKAS, LISA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$5,181
|
ALS
|
NCRR
|
2M01RR001066-31
|
8230
|
CLINICAL TRIAL: CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS
|
KRIVICKAS, LISA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$8,742
|
ALS
|
NCRR
|
2M01RR001066-31
|
8235
|
CLINICAL TRIAL: PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERA
|
BROWN, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$1,619
|
ALS
|
NCRR
|
2M01RR001066-31
|
8265
|
OPEN LABEL CREATINE MONOHYDRATE DOSAGE-ESCALATION STUDY
|
DIBERNARDO, ALLITIA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$5,666
|
ALS
|
NIA
|
1Z01AG000315-08
|
|
Dietary Modification Of Brain Aging And Neurodegenerative Disorders
|
MATTSON, MARK
|
NIH
|
|
$1,080,921
|
ALS
|
NIA
|
1Z01AG000933-01
|
|
Genome wide SNP analysis in Amyotrophic Lateral Sclerosis
|
SINGLETON, ANDREW
|
NIH
|
|
$191,764
|
ALS
|
NIA
|
1Z01AG000941-01
|
|
The Role of ALS2/Alsin in ALS and Motor Neuron Diseases
|
CAI, HUAIBIN
|
NIH
|
|
$299,151
|
ALS
|
NIA
|
1Z01AG000943-01
|
|
The Pathogenic Mechanism of ALS-related TDP-43 Mutations
|
CAI, HUAIBIN
|
NIH
|
|
$107,388
|
ALS
|
NIA
|
1Z01AG000946-01
|
|
The Function of dynactin p150glued in Axonal Transport and Motor Neuron Diseases
|
CAI, HUAIBIN
|
NIH
|
|
$155,329
|
ALS
|
NIA
|
1Z01AG000959-05
|
|
Pathobiological Studies of Neurodegenerative Diseases
|
CAI, HUAIBIN
|
NIH
|
|
$210,940
|
ALS
|
NCI
|
1Z01BC010822-02
|
|
Molecular Determinants of Chromosome Transmission and Cell Cycle Regulation
|
BASRAI, MUNIRA
|
NIH
|
|
$824,008
|
ALS
|
NIEHS
|
1Z01ES049004-17
|
|
Statistical Methods In Human Development/clinical Studies
|
UMBACH, DAVID
|
NIH
|
|
$72,225
|
ALS
|
NIEHS
|
1Z01ES049005-17
|
|
Lead And Other Neurotoxins As Risk Factors For Amyotrophic Lateral Sclerosis
|
SANDLER, DALE
|
NIH
|
|
$69,588
|
ALS
|
NINDS
|
1Z01NS002976-10
|
|
Spinal And Peripheral Mechanisms Of Human Motor Control
|
FLOETER, MARY KAY
|
NIH
|
|
$725,290
|